Initial Treatment Approach for Vasculitis

Classification and Assessment

• In suspected ANCA-associated vasculitis with positive serology, treatment should not be delayed while waiting for biopsy results, especially in rapidly deteriorating patients 1

Initial Treatment Approach by Vasculitis Type

• The European League Against Rheumatism recommends initiating high-dose glucocorticoid therapy immediately for induction of remission in large vessel vasculitis 2, 3
• The American College of Rheumatology suggests maintaining high-dose glucocorticoids for one month before gradual tapering in large vessel vasculitis 2
• For Giant Cell Arteritis with symptoms, immediate initiation of high-dose glucocorticoids is recommended to reduce recurrent stroke risk, according to the American Heart Association 4
• Consider adjunctive immunosuppressive therapy, such as methotrexate or tocilizumab, as steroid-sparing agents for Giant Cell Arteritis, as recommended by the European League Against Rheumatism 3, 4
• For Takayasu Arteritis, all patients should receive non-biological glucocorticoid-sparing agents in combination with glucocorticoids, according to the European League Against Rheumatism 3

ANCA-Associated Vasculitis

• Combination therapy with glucocorticoids and either rituximab or cyclophosphamide is recommended as initial treatment for ANCA-associated vasculitis, according to the Kidney Disease: Improving Global Outcomes guideline 1
• For patients with markedly reduced or rapidly declining renal function, cyclophosphamide plus glucocorticoids, or a combination of rituximab and cyclophosphamide should be considered, as recommended by the Kidney Disease: Improving Global Outcomes guideline 1
• Factors favoring cyclophosphamide include severe renal disease, according to the Kidney Disease: Improving Global Outcomes guideline 1
• Factors favoring rituximab include younger patients concerned about fertility, and those with relapsing disease, as suggested by the Kidney Disease: Improving Global Outcomes guideline 1

Dosing and Administration

• Glucocorticoids: Initial dose of 1 mg/kg/day (maximum 60 mg/day) for large vessel vasculitis, as recommended by the European League Against Rheumatism 2

Monitoring and Follow-up

• ANCA persistence, increase in ANCA levels, or change from negative to positive may predict future relapse and should be considered when making treatment decisions, according to the Kidney Disease: Improving Global Outcomes guideline 1

Special Considerations

• Patients with AAV should be treated at centers with experience in AAV management, as recommended by the Kidney Disease: Improving Global Outcomes guideline 1
• For severe disease with pulmonary hemorrhage or rapidly progressive renal disease, more aggressive initial therapy may be required, according to the Kidney Disease: Improving Global Outcomes guideline 1
• The combination of rituximab and cyclophosphamide can be considered for severe disease, as suggested by the Kidney Disease: Improving Global Outcomes guideline 1

Common Pitfalls to Avoid

• Delaying treatment while waiting for biopsy results in rapidly deteriorating patients, as warned by the Kidney Disease: Improving Global Outcomes guideline 1
• Using alternate-day glucocorticoid therapy, which increases risk of relapse, according to the European League Against Rheumatism 2
• Inadequate initial immunosuppression in severe disease, as cautioned by the Kidney Disease: Improving Global Outcomes guideline 1

Vasculitis Diagnosis and Treatment

Diagnostic Approach

• Patients with suspected vasculitis should be categorized according to vessel size and disease severity to guide appropriate management, as recommended by the European League Against Rheumatism 5, 6
• Disease activity should be assessed using validated tools such as Birmingham Vasculitis Activity Score (BVAS), with a strength of evidence rated as high 7
• Patients with ANCA-associated vasculitis (AAV) should be categorized as: localized, early systemic, generalized, severe, or refractory disease, according to the American College of Rheumatology 6
• ANCA testing, including indirect immunofluorescence and ELISA, should be performed in appropriate clinical contexts, with a sensitivity of 80-90% 8
• Basic laboratory tests should include comprehensive metabolic panel, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), as recommended by the American College of Rheumatology 7, 9
• Urinalysis with microscopic examination and quantification of proteinuria should be performed to assess renal involvement, with a strength of evidence rated as moderate 7

Treatment Approach

• Early initiation of high-dose glucocorticoid therapy is recommended for induction of remission in large vessel vasculitis, with an initial dose of 1 mg/kg/day, as recommended by the European League Against Rheumatism 9
• Combination of cyclophosphamide and glucocorticoids is recommended for generalized ANCA-associated vasculitis, with an oral cyclophosphamide dose of 2 mg/kg/day, as recommended by the American College of Rheumatology 6
• Rituximab has shown a 91% remission rate in open-label trials for refractory ANCA-associated vasculitis, with a strength of evidence rated as low 8
• Prophylaxis against Pneumocystis jiroveci and osteoporosis should be considered for patients on immunosuppressive therapy, as recommended by the European League Against Rheumatism 6, 9

Monitoring and Follow-up

• Clinical monitoring aided by inflammatory markers should inform treatment decisions, with a strength of evidence rated as moderate 10
• Regular assessment of disease activity using structured clinical examination and validated tools, such as BVAS, should be performed, as recommended by the American College of Rheumatology 7
• Monitor for drug toxicity, including acute fall in white cell count, progressive leucopenia, and renal function, as recommended by the European League Against Rheumatism 6, 7

Treatment for Vasculitis

Initial Assessment and Disease Classification

• The American College of Nephrology recommends vasculitis treatment requires immediate combination therapy with high-dose glucocorticoids plus either rituximab or cyclophosphamide, with the specific regimen determined by vasculitis type, disease severity, and organ involvement, particularly renal function and pulmonary status 11

Treatment by Vasculitis Type

• The European Renal Association recommends induction therapy for severe/generalized ANCA-associated vasculitis, including glucocorticoids, such as prednisolone 1 mg/kg/day, and either rituximab 375 mg/m² weekly for 4 weeks or cyclophosphamide 2 mg/kg/day orally 11
• The American College of Rheumatology suggests that rituximab is preferred over cyclophosphamide for relapsing disease, with a 67% vs 42% remission rate, and for younger patients concerned about fertility 11
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend adjunctive therapy for severe disease, including plasma exchange for patients with dialysis requirement, rapidly progressive renal failure, or diffuse alveolar hemorrhage with hypoxemia 11

Maintenance Therapy

• The European League Against Rheumatism (EULAR) recommends three evidence-based options for maintenance therapy: rituximab, azathioprine, and mycophenolate mofetil, with glucocorticoid maintenance continued at 5-7.5 mg/day for 2 years, then reduced by 1 mg every 2 months 11
• The American Society of Nephrology suggests that methotrexate should not be used in patients with GFR <60 ml/min per 1.73 m² 11

Treatment Duration

• The National Institute for Health and Care Excellence (NICE) recommends a minimum maintenance therapy duration of at least 18-24 months for initial remission, with extended therapy to 4 years after diagnosis reducing relapse risk 11

Treatment of Vasculitis

Induction Therapy

• The European League Against Rheumatism recommends initiating combination therapy immediately with cyclophosphamide (2 mg/kg/day oral or IV pulses) plus high-dose glucocorticoids (prednisolone 1 mg/kg/day, maximum 60 mg/day) for severe systemic vasculitis 12
• For generalized/severe ANCA-associated vasculitis, cyclophosphamide 2 mg/kg/day oral (maximum 200 mg/day) OR intravenous pulses PLUS prednisolone 1 mg/kg/day (maximum 60 mg/day) is recommended 12
• Methotrexate (oral or parenteral) plus glucocorticoids can be used as a less toxic alternative for non-organ threatening or non-life threatening disease 12, 13
• The American College of Rheumatology suggests using rituximab 375 mg/m² weekly for 4 weeks as an alternative to cyclophosphamide for patients with relapsing disease or fertility concerns 12

Maintenance Therapy

• Once remission is achieved, transition to low-dose glucocorticoids (5-7.5 mg/day) PLUS one of the following: azathioprine, rituximab, leflunomide, methotrexate, or mycophenolate mofetil 12, 13
• Azathioprine is the first-line choice with the strongest evidence 12, 13

Refractory Disease Management

• For patients failing standard therapy or experiencing relapse, rituximab achieves a 91% remission rate in refractory AAV 13
• Intravenous immunoglobulin (IVIG) 2 gm/kg can be used for short-term control, but serum immunoglobulin levels must be measured first due to anaphylaxis risk in IgA deficiency 13

Monitoring Requirements

• Structured clinical assessment, urinalysis, and basic laboratory tests should be performed at every clinical visit 12
• Investigate persistent unexplained hematuria in all patients with prior cyclophosphamide exposure due to bladder cancer risk 12

Critical Pitfalls to Avoid

• Tobacco smokers on cyclophosphamide develop bladder cancer at lower doses and earlier than non-smokers 12

Induction and Maintenance Therapy for ANCA‑Associated Vasculitis

Disease Severity Classification

• Localized disease – involvement of the upper or lower respiratory tract without systemic symptoms.
• Early systemic disease – systemic involvement but no organ‑threatening features.
• Generalized disease – renal or other organ‑threatening involvement with serum creatinine < 500 µmol/L (≈5.6 mg/dL).
• Severe disease – vital‑organ failure or serum creatinine > 500 µmol/L.
• Refractory disease – progression despite glucocorticoids and cyclophosphamide.  14

Induction Therapy

Glucocorticoid Regimen

• Initiate oral prednisolone 1 mg/kg/day (maximum 60 mg) immediately at diagnosis.  [15][16]
• Maintain this high dose for ≥ 1 month before any taper.  [14][16]
• Do not reduce below 15 mg/day during the first 3 months.  14
• Taper to a maintenance dose of 5–7.5 mg/day by 6 months.  16
• For rapid disease control, give IV methylprednisolone 500–1000 mg/day for 3–5 days.  15

Choice of Immunosuppressive Agent

Specific Dosing Regimens

• Rituximab – 375 mg/m² IV weekly × 4 weeks or 1000 mg IV on days 1 and 15.  [15][16]

• Cyclophosphamide –

  • Oral: 2 mg/kg/day for 3–6 months (reduce to 1.5 mg/kg/day if age > 60 y; 1.0 mg/kg/day if age > 70 y).  16
  • IV pulses: 15 mg/kg at weeks 0, 2, 4, 7, 10, 13 (dose reductions for older patients as above).  16
  • Reduce dose by 0.5 mg/kg/day (oral) or 2.5 mg/kg (IV) when GFR < 30 mL/min/1.73 m².  16

• Methotrexate (for early systemic or non‑organ‑threatening disease) – start 15 mg/week, increase to 20–25 mg/week over 1–2 months; contraindicated if GFR < 60 mL/min/1.73 m².  [14][16]

Adjunctive Therapies

Plasma Exchange

• Perform 7 exchanges over 14 days in patients with any of the following: serum creatinine > 3.4 mg/dL, dialysis requirement, rapidly rising creatinine, or diffuse alveolar hemorrhage with hypoxemia.  [14][16]
• Evidence shows plasma exchange improves renal survival in severe renal disease.  14

Avacopan

• Avacopan 30 mg twice daily can replace glucocorticoids when combined with rituximab or cyclophosphamide, especially in patients at high risk for steroid toxicity and those with low baseline GFR.  16

Mandatory Prophylaxis for Cyclophosphamide

• Pneumocystis jiroveci prophylaxis – trimethoprim‑sulfamethoxazole 800/160 mg on alternate days (or 400/80 mg daily; pentamidine if contraindicated).  14
• Mesna – oral or IV to bind acrolein and prevent hemorrhagic cystitis.  14
• Bone protection – calcium, vitamin D, and bisphosphonate therapy for glucocorticoid‑induced osteoporosis.  14

Maintenance Therapy

• After achieving remission (typically 3–6 months), transition to rituximab or azathioprine plus low‑dose glucocorticoids.  16

Rituximab Maintenance (preferred for relapsing disease)

• 500 mg IV every 6 months (MAINRITSAN protocol) or 1000 mg IV every 4 months (RITAZAREM protocol).
• Reduces major relapse rate to ≈ 5 % versus ≈ 29 % with azathioprine.  16

Azathioprine Maintenance (first‑line with strongest evidence)

• 1.5–2 mg/kg/day for 18–24 months, then taper to 1 mg/kg/day until 4 years after diagnosis; reduce by 25 mg every 3 months thereafter.  16

Alternative Agents (if azathioprine intolerant)

• Mycophenolate mofetil 2000 mg/day (divided doses).  16
• Methotrexate 20–25 mg/week only if GFR > 60 mL/min/1.73 m².  16

Glucocorticoid Maintenance

• Continue 5–7.5 mg/day prednisolone for at least 18–24 months; after 2 years, taper by 1 mg every 2 months.  16

Duration of Maintenance

• Minimum 18–24 months of maintenance therapy; extending to 4 years further reduces relapse risk.  16
• Factors favoring extended therapy: PR3‑ANCA positivity, prior relapses, persistent or rising ANCA titers, and pulmonary involvement.  16

Monitoring

• Cyclophosphamide – CBC weekly for the first cycle, then every 2 weeks; adjust or stop if leukopenia develops.  14
• Investigate any persistent unexplained hematuria in patients previously exposed to cyclophosphamide because of bladder‑cancer risk.  14

Critical Pitfalls to Avoid

• Never use alternate‑day glucocorticoid regimens (increases relapse risk).  14
• Never prescribe methotrexate when GFR < 60 mL/min/1.73 m².  16
• Never omit Pneumocystis prophylaxis in patients receiving cyclophosphamide.  [14][16]
• Ensure adequate initial immunosuppression in severe disease to avoid increased mortality.  16

Management of Uveitis in ANCA‑Associated Vasculitis – Evidence‑Based Guideline Summary

Disease Classification & Treatment Urgency

• Ocular involvement in ANCA‑associated vasculitis (AAV) is considered organ‑threatening, placing patients in the “generalized” or “severe” disease category and mandating aggressive systemic immunosuppression rather than localized therapy. 17
• Vision‑threatening uveitis constitutes a major relapse of AAV and requires intensification of immunosuppressive therapy, analogous to life‑ or organ‑threatening manifestations such as diffuse alveolar hemorrhage or rapidly progressive glomerulonephritis. 18
• When clinical features are compatible with AAV and ANCA serology is positive, treatment must not be delayed for additional diagnostic work‑up; immediate immunosuppression is essential to prevent permanent vision loss. 18

Monitoring & Follow‑Up

• A structured ophthalmologic examination (visual acuity, intra‑ocular pressure, slit‑lamp assessment, and dilated fundoscopy) should be performed at every clinical visit to evaluate ocular disease activity. 17
• ANCA titers that persist, increase, or convert from negative to positive may forecast future relapse and should be incorporated into therapeutic decision‑making. 18

Therapeutic Options for Non‑Organ‑Threatening Uveitis

• For isolated anterior uveitis without posterior segment involvement and with preserved renal function (estimated GFR > 60 mL/min/1.73 m²), methotrexate 20–25 mg weekly can be used as an alternative systemic agent. 19

Multidisciplinary Management

• Patients with AAV should be managed in centers experienced in AAV care, equipped for rapid diagnosis, with ready access to rituximab, plasma‑exchange, and intensive‑care or dialysis facilities when needed. 18
• Ongoing coordination with ophthalmology is required for continuous assessment of ocular disease activity and detection of complications. 17
• A holistic approach is recommended: clinicians must evaluate and address permanent damage to other organs (kidneys, lungs, nervous system) and provide appropriate supportive therapies, reflecting the systemic nature of AAV. 17